Seizure Treatments Market

The global Seizure Treatments market was valued at USD 20.55 billion in 2025 and is estimated at USD 21.55 billion in 2026. The market is projected to reach USD 31.47 billion by 2034, exhibiting an endpoint-consistent 4.9% CAGR during 2026–2034.

Seizure treatments include chronic antiseizure medicines, rescue therapies for seizure clusters, epilepsy surgery, neurostimulation devices and dietary or other specialist approaches. The market is dominated by pharmacotherapy, but treatment value increasingly extends into implantable neuromodulation and minimally invasive surgery for drug-resistant epilepsy. Product choice depends on seizure type, epilepsy syndrome, age, comorbidities, reproductive considerations, route requirements and prior treatment response.

The underlying treatment population is substantial. WHO estimates around 50 million people worldwide have epilepsy, nearly 80% of whom live in low- and middle-income countries. Up to 70% could become seizure-free with appropriate diagnosis and treatment, yet treatment gaps remain large. This creates two simultaneous market opportunities: continued innovation for patients with persistent seizures despite therapy and much broader access to established medicines in undertreated countries.

The 2026 competitive environment is being reshaped by loss of exclusivity, generic entry, reimbursement and device innovation. FDA granted multiple first generic approvals for brivaracetam injection and oral solution in February 2026. LivaNova's 2026 Medicare hospital outpatient reimbursement increased materially for VNS Therapy procedures, while NeuroPace received FDA approval for its ECoG Assistant AI feature in May 2026 and published three-year RNS data showing an 82% median seizure reduction in drug-resistant focal epilepsy.

The study covers pharmacologic, surgical and device-based management of recurrent seizures and epilepsy, preserving the market's core drug-generation and route-of-administration segmentation while adding clinically relevant treatment modalities.

High epilepsy prevalence sustains chronic treatment demand

Epilepsy affects approximately 50 million people globally and requires long-term management in many patients. Recurring prescriptions create a durable pharmaceutical demand base, while periodic breakthrough seizures generate rescue-therapy use.

A large drug-resistant population supports surgery and neuromodulation

Drug-resistant epilepsy is generally recognized after failure of two appropriately selected antiseizure medicines. The Epilepsy Foundation estimates roughly one in three adults and one in four children with epilepsy are drug resistant, creating demand for comprehensive epilepsy centers, surgery, VNS, RNS and DBS.

Generic entry is changing revenue mix in established medicines

FDA approved multiple first generics of brivaracetam solution and injection in February 2026. UCB reported BRIVIACT loss of U.S. market exclusivity in February 2026, illustrating how value migrates from mature brands toward newer molecules and devices after generic competition begins.

Rescue therapies expand care outside hospitals

Intranasal midazolam and diazepam provide rapid at-home treatment of seizure clusters. FDA expanded VALTOCO use to children aged two years and older in 2025, widening the eligible rescue population and reinforcing caregiver-administered therapy.

Treatment gaps constrain market realization in low-income countries

WHO estimates three quarters of people with epilepsy in low-income countries do not receive the treatment they need. Limited specialist access, medicine availability and diagnosis restrict current revenue but represent a large public-health and long-term market opportunity.

Third-generation medicines are becoming the main branded growth engine

Cenobamate, brivaracetam, perampanel and other newer agents offer differentiated efficacy or tolerability in focal epilepsy. SK Life Science filed an NDA for a cenobamate oral suspension that FDA accepted for review in June 2026, expanding formulation-based lifecycle growth.

AI is entering implantable epilepsy management

NeuroPace received FDA approval in May 2026 for ECoG Assistant, an AI-enabled clinician feature that helps review long-term intracranial EEG data from RNS patients. This extends device value beyond stimulation into data interpretation.

VNS reimbursement improves procedural economics

CMS assigned VNS Therapy new patient implants to New Technology APC 1580 for 2026. LivaNova reported roughly 48% higher hospital outpatient payment for new implants versus 2025, reducing a significant provider adoption barrier.

Generic brivaracetam creates access and price competition

FDA first-generic approvals in February 2026 covered both brivaracetam oral solution and injection, broadening lower-cost access as BRIVIACT exclusivity expires in major markets.

Seizure-cluster treatment is moving toward caregiver-friendly routes

VALTOCO and NAYZILAM have established nasal rescue therapy as a major alternative to rectal diazepam. Easier administration supports wider use in schools, workplaces, travel and home settings.

Treatment generally progresses from correctly classified antiseizure medication toward specialist evaluation for surgery, neurostimulation or dietary therapy when seizures remain uncontrolled.

Third-Generation AEDs lead market value at approximately 42.7%, followed by second-generation agents and mature first-generation medicines.

Oral products dominate with approximately 84.7% of 2025 value because seizure prevention is usually long-term outpatient therapy.

Antiseizure Medication is the largest modality, while neurostimulation and surgery provide high-value options for drug-resistant epilepsy.

Focal-onset seizures represent the largest treated segment because they are common in adults and are the principal indication for multiple branded newer therapies and neuromodulation devices.

Hospitals & Epilepsy Centers are the largest high-value end-user setting because complex diagnosis, surgery, VNS/RNS/DBS implantation and refractory-care evaluation are concentrated there.

North America

North America is the largest regional market. The United States combines broad epilepsy diagnosis, specialist centers, high branded-drug use and reimbursement for implantable neurostimulation. In 2026, CMS reimbursement changes improved VNS procedure economics, NeuroPace launched AI-enabled RNS support and multiple brivaracetam generics entered.

Europe

Europe has mature epilepsy treatment networks and broad generic use. UCB remains a major regional epilepsy supplier, but BRIVIACT exclusivity expired in 2026, accelerating generic competition. Germany, France, the United Kingdom, Italy and Spain are the principal national markets.

Asia-Pacific

Asia-Pacific is the fastest-growing region because it contains a large share of the global epilepsy population and treatment access is improving. Japan has a mature antiseizure-drug market, while China and India combine expanding neurology care with large generic manufacturing bases.

Latin America

Brazil and Mexico lead demand through public and private neurology systems. Generic medicines dominate much chronic treatment, while access to epilepsy surgery and advanced neurostimulation is concentrated in major referral centers.

Middle East & Africa

The region has a large treatment gap. Gulf countries support specialist centers and premium branded therapies, while lower-income countries face shortages of trained clinicians, EEG access and reliable antiseizure-medicine supply.

The seizure-treatment market combines mature generic pathways, controlled-substance rescue medicines and high-risk implantable devices, creating different regulatory and reimbursement requirements across modalities.

Competition spans branded CNS pharmaceutical companies, generic manufacturers and specialized neuromodulation companies.

• UCB
• SK Life Science / SK Biopharmaceuticals
• Jazz Pharmaceuticals
• Neurelis
• LivaNova
• NeuroPace
• Medtronic
• Abbott
• Pfizer
• Novartis
• Sanofi
• Sunovion / Sumitomo Pharma
• Bausch Health
• Eisai

The global Seizure Treatments market is projected to grow from USD 21.55 billion in 2026 to USD 31.47 billion by 2034, at an endpoint-consistent 4.9% CAGR. Growth will be driven by newer antiseizure medicines, rescue formulations, refractory-epilepsy devices and broader treatment access, while genericization will moderate revenue in mature molecules.

The study supports epilepsy portfolio strategy, drug lifecycle planning, neuromodulation investment, rescue-therapy commercialization and competitive benchmarking.